riluzole has been researched along with Multiple System Atrophy Syndrome in 5 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Riluzole is a neuroprotective agent that is currently tested for the treatment of multiple system atrophy (MSA)." | 9.10 | Riluzole and blood pressure in multiple system atrophy. ( Arnold, G; Jordan, J; Lipp, A; Luft, FC; Stoffels, M; Tank, J, 2003) |
| "Riluzole was generally well tolerated." | 6.72 | Placebo-controlled trial of riluzole in multiple system atrophy. ( Diem-Zangerl, A; Mueller, J; Peralta, C; Poewe, W; Puschban, Z; Seppi, K; Wenning, GK, 2006) |
| "Riluzole was administered prior to and consecutively for ten days following double lesion placement in the left-sided medial forebrain bundle and ipsilateral striatum." | 5.33 | Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy). ( Diguet, E; Poewe, W; Puschban, Z; Sather, T; Scherfler, C; Stefanova, N; Tison, F; Wenning, GK, 2005) |
| "Riluzole is a neuroprotective agent that is currently tested for the treatment of multiple system atrophy (MSA)." | 5.10 | Riluzole and blood pressure in multiple system atrophy. ( Arnold, G; Jordan, J; Lipp, A; Luft, FC; Stoffels, M; Tank, J, 2003) |
| "Riluzole was generally well tolerated." | 2.72 | Placebo-controlled trial of riluzole in multiple system atrophy. ( Diem-Zangerl, A; Mueller, J; Peralta, C; Poewe, W; Puschban, Z; Seppi, K; Wenning, GK, 2006) |
| "Riluzole was administered prior to and consecutively for ten days following double lesion placement in the left-sided medial forebrain bundle and ipsilateral striatum." | 1.33 | Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy). ( Diguet, E; Poewe, W; Puschban, Z; Sather, T; Scherfler, C; Stefanova, N; Tison, F; Wenning, GK, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bensimon, G | 1 |
| Ludolph, A | 1 |
| Agid, Y | 1 |
| Vidailhet, M | 1 |
| Payan, C | 1 |
| Leigh, PN | 1 |
| Stefanova, N | 2 |
| Bücke, P | 1 |
| Duerr, S | 1 |
| Wenning, GK | 3 |
| Lipp, A | 1 |
| Tank, J | 1 |
| Stoffels, M | 1 |
| Arnold, G | 1 |
| Luft, FC | 1 |
| Jordan, J | 1 |
| Scherfler, C | 1 |
| Sather, T | 1 |
| Diguet, E | 1 |
| Puschban, Z | 2 |
| Tison, F | 1 |
| Poewe, W | 2 |
| Seppi, K | 1 |
| Peralta, C | 1 |
| Diem-Zangerl, A | 1 |
| Mueller, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy[NCT02422485] | Phase 1 | 10 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Phase 3 Study of Riluzole in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) (Parkinson's Plus Syndromes)[NCT00211224] | Phase 3 | 800 participants | Interventional | 2000-04-30 | Terminated | ||
| A 6 Month, Open-Label, Pilot Futility Clinical Trial of Monthly Young Healthy Male Donor Plasma Transfusions for Progressive Supranuclear Palsy[NCT02460731] | Phase 1 | 6 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies[NCT01056965] | Phase 1 | 12 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticoba[NCT02133846] | Phase 1 | 44 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for riluzole and Multiple System Atrophy Syndrome
| Article | Year |
|---|---|
Multiple system atrophy: an update.
Topics: alpha-Synuclein; Excitatory Amino Acid Antagonists; Humans; Multiple System Atrophy; Prognosis; Rilu | 2009 |
3 trials available for riluzole and Multiple System Atrophy Syndrome
| Article | Year |
|---|---|
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole and blood pressure in multiple system atrophy.
Topics: Aged; Area Under Curve; Blood Pressure; Cardiac Output; Cardiography, Impedance; Excitatory Amino Ac | 2003 |
Placebo-controlled trial of riluzole in multiple system atrophy.
Topics: Aged; Cross-Over Studies; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Multiple Sys | 2006 |
1 other study available for riluzole and Multiple System Atrophy Syndrome
| Article | Year |
|---|---|
Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy).
Topics: Animals; Biomarkers; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine and cAMP-Regulat | 2005 |